CASI Pharmaceuticals director Barbara Krebs-Pohl resigns
CASI Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing CID-103 for organ transplant rejection and autoimmune diseases, reported that Dr. Barbara Krebs-Pohl has resigned as a director, effective May 31, 2026.
Rhea-AI Filing Summary
CASI Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing CID-103 for organ transplant rejection and autoimmune diseases, reported that Dr. Barbara Krebs-Pohl has resigned as a director, effective May 31, 2026. The company states her resignation was not due to any disagreement with the company. After stepping down, she agreed to continue supporting CASI as an independent consultant on mutually agreed terms.
Positive
- None.
Negative
- None.
Key Figures
Form type: Form 6-K
Director resignation effective date: May 31, 2026
Report month: June 2026
3 metrics
Form type
Form 6-K
Report of foreign private issuer
Director resignation effective date
May 31, 2026
Effective date of Dr. Barbara Krebs-Pohl’s resignation
Report month
June 2026
Month covered by this foreign private issuer report
Key Terms
Form 6-K, foreign private issuer, clinical-stage biopharmaceutical company, forward-looking statements, +1 more
5 terms
Form 6-K regulatory
"Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"
A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.
foreign private issuer regulatory
"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
clinical-stage biopharmaceutical company financial
"CASI Pharmaceuticals, Inc. ..., a clinical-stage biopharmaceutical company developing CID-103"
A clinical-stage biopharmaceutical company develops drugs or medical therapies that are being tested in people in formal clinical trials but do not yet have any approved, marketed products. For investors, these firms behave like prototype makers: their value depends heavily on trial results and regulatory decisions, so they can swing widely on a single study, consume cash while testing, and offer either large upside if trials succeed or big downside if they fail.
forward-looking statements regulatory
"This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Private Securities Litigation Reform Act of 1995 regulatory
"under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995"
FAQ
What did CASI Pharmaceuticals (CASI) announce in this Form 6-K?
CASI Pharmaceuticals announced that director Dr. Barbara Krebs-Pohl resigned from the board effective May 31, 2026. The company also noted that she will continue working with CASI as an independent consultant on mutually agreed terms after her resignation.
When did CASI director Dr. Barbara Krebs-Pohl’s resignation become effective?
Her resignation became effective on May 31, 2026. CASI Pharmaceuticals disclosed this date in its report and added that, despite leaving the board, she agreed to remain involved with the company as an independent consultant going forward.
Was Dr. Barbara Krebs-Pohl’s resignation from CASI (CASI) due to a disagreement?
No, her resignation was explicitly stated as not due to any disagreement with CASI Pharmaceuticals. The company clarified this point and further indicated she would continue collaborating with CASI as an independent consultant under mutually agreed terms.
What ongoing role will Dr. Barbara Krebs-Pohl have with CASI Pharmaceuticals?
After resigning as a director, Dr. Barbara Krebs-Pohl agreed to serve as an independent consultant to CASI Pharmaceuticals. The company noted that this consulting relationship will be based on mutually agreed terms between her and CASI following her board departure.
What type of company is CASI Pharmaceuticals (CASI) according to this report?
CASI Pharmaceuticals is described as a clinical-stage biopharmaceutical company. It is developing CID-103, an anti-CD38 monoclonal antibody, intended for patients with organ transplant rejection and autoimmune diseases, according to the information included in the June 2026 report.
What forward-looking statements caution did CASI Pharmaceuticals include?
CASI included a standard forward-looking statements caution under the U.S. Private Securities Litigation Reform Act of 1995. It noted such statements involve risks and uncertainties and directed readers to the company’s SEC filings for further information on these risk factors.
AI-generated analysis. How Rhea-AI works. Not financial advice.
